Provided by Tiger Fintech (Singapore) Pte. Ltd.

CMS

14.210
+0.0400.28%
Volume:1.05M
Turnover:14.90M
Market Cap:34.67B
PE:19.44
High:14.300
Open:14.170
Low:14.000
Close:14.170
52wk High:15.630
52wk Low:6.523
Shares:2.44B
HK Float Shares:2.44B
Volume Ratio:1.35
T/O Rate:0.04%
Dividend:0.30
Dividend Rate:2.10%
EPS(LYR):0.731
ROE:9.91%
ROA:5.58%
PB:1.86
PE(LYR):19.44
PS:4.03

Loading ...

China Medical System Holdings Receives NMPA Approval to Conduct Phase III Clinical Trials of Innovative MG-K10 Monoclonal Antibody for Chronic Spontaneous Urticaria in Mainland China

Reuters
·
Sep 28

CMS (00867): Class 1 New Drug MG-K10 Humanized Monoclonal Antibody Injection Receives Additional Phase III Clinical Trial Approval for Chronic Spontaneous Urticaria Indication

Stock News
·
Sep 28

China Medical System Holdings Limited Approval of Phase Iii Drug Clinical Trials for Chronic Spontaneous Urticaria Indication of Mg-K10

THOMSON REUTERS
·
Sep 28

China Medical System (867.HK; 8a8.SG) Positive Results From China Phase 3 Clinical Trial of Innovative Drug Ruxolitinib Cream With Ad Indication

THOMSON REUTERS
·
Sep 28

China Medical System Holdings Limited Approval of Drug Clinical Trials for Uterine Fibroids Indication of Innovative Drug CMS-D002

THOMSON REUTERS
·
Sep 26

CMS (00867): Innovative Drug Ruxolitinib Phosphate Cream Achieves Positive Results in Phase III Clinical Trial for Atopic Dermatitis in China

Stock News
·
Sep 26

CMS (00867): Innovative GnRH Receptor Antagonist CMS-D002 Receives Clinical Trial Approval for Uterine Fibroids Indication

Stock News
·
Sep 26

China Medical System Holdings Announces Positive Phase 3 Trial Results for Ruxolitinib Cream in Chinese Atopic Dermatitis Patients

Reuters
·
Sep 26

China Medical System Holdings Ltd. Receives NMPA Approval to Initiate Clinical Trials for Innovative GnRH Receptor Antagonist CMS-D002 in Uterine Fibroids

Reuters
·
Sep 26

China Medical System Holdings Ltd - Gets Nmpa Approval for CMS-D002 Trial

THOMSON REUTERS
·
Sep 26

China Medical System (867.HK; 8a8.SG) Signed Collaboration Agreements for Two Innovative Biologics Used for Passive Immunization Against Tetanus and Rabies

THOMSON REUTERS
·
Sep 23

CMS (00867; 8A8.SG) Reaches Cooperation Agreement for Two Innovative Biological Products: Vikontamab Injection for Tetanus Passive Immunization and Siravemab Injection for Rabies Passive Immunization

Stock News
·
Sep 23

BRIEF-China Medical System Entered Into Two Separate Exclusive Collaboration Agreements

Reuters
·
Sep 22

China Medical System Holdings Ltd. Announces Collaboration Agreements for Innovative Biologic Products

Reuters
·
Sep 22

China Medical System - Entered Into Two Seperate Exclusive Collaboration Agreements With Chongqing Genrix Biopharmaceutical

THOMSON REUTERS
·
Sep 22

China Medical System - Under Deals, Obtained Exclusive Commercialization Rights for Vecantoxatug and Silevimig Injections in Mainland China, Others

THOMSON REUTERS
·
Sep 22

CISI FIN Maintains "Buy" Rating for CMS, Exclusive and Innovative Products Drive New Growth

Stock News
·
Sep 16

China Medical System Holdings (SEHK:867) Reports Positive Earnings Growth for H1 2025

Simply Wall St.
·
Sep 12

Haitong International: Maintains "Outperform" Rating on CMS (00867) with Target Price of HK$18.38

Stock News
·
Sep 11

CITIC Securities Maintains "Buy" Rating for CMS (00867), Citing Innovation-Driven Long-Term Growth Potential

Stock News
·
Sep 09